Fund Discloses Increased Mineralys Bet Amid 200% Stock Run as New Drug Application Nears
Key Points
New York City-based Suvretta Capital Management increased its MLYS position by 387,641 shares in the third quarter.
The overall position value increased by $57.25 million from the previous period.
As of September 30, Suvretta reported holding 2.13 million MLYS shares valued at $80.85 milion.
- These 10 stocks could mint the next wave of millionaires ›
On November 14, New York City-based Suvretta Capital Management disclosed a buy of 387,641 shares of Mineralys Therapeutics (NASDAQ:MLYS) that contributed to an overall position increase of about $57.25 million.
What Happened
Suvretta Capital Management, a U.S.-based investment adviser, reported in a November 14 SEC filing that it increased its stake in Mineralys Therapeutics (NASDAQ:MLYS) during the third quarter. The fund acquired 387,641 additional shares, bringing total holdings to 2.13 million shares worth $80.85 million as of September 30. The fund reported 93 total positions for the quarter.
What Else to Know
This buy brings the fund’s MLYS stake to 2.07% of 13F AUM after the third-quarter increase.
Top holdings after the filing:
- NASDAQ:ARQT: $197.51 million (5.99% of AUM)
- NASDAQ:BNTC: $138.57 million (4.20% of AUM)
- NASDAQ:META: $125.56 million (3.81% of AUM)
- NASDAQ:LEGN: $124.51 million (3.77% of AUM)
- NASDAQ:ETNB: $121.72 million (3.69% of AUM)
As of Tuesday, shares were priced at $36.96, up a staggering 206% and well outperforming the S&P 500, which is up 15% in the same period.
Company Overview
| Metric | Value |
|---|---|
| Price (as of Tuesday) | $36.96 |
| Market Capitalization | $2.93 billion |
| Net Income (TTM) | ($171.36 million) |
| One-Year Price Change | 206% |
Company Snapshot
- Mineralys Therapeutics' lead product is lorundrostat, an orally administered, highly selective aldosterone synthase inhibitor targeting uncontrolled or resistant hypertension.
- The company operates a clinical-stage biopharmaceutical model, generating value through the research, development, and potential commercialization of proprietary therapies for cardiovascular diseases.
- Primary customers are expected to include healthcare providers and patients suffering from hypertension, particularly those with limited treatment options.
Mineralys Therapeutics is a clinical-stage biotechnology company focused on developing innovative therapies for hypertension and related cardiovascular conditions. The company's strategic emphasis on lorundrostat positions it to address significant unmet needs in resistant hypertension. With a specialized approach and a proprietary drug candidate, Mineralys aims to establish a competitive edge in the cardiovascular therapeutics market.
Foolish Take
It’s a pivotal moment for Mineralys, which is no longer a concept-stage biotech living quarter to quarter. After completing enrollment in its Phase 2 Explore-OSA trial and signaling plans to submit a New Drug Application for lorundrostat by early 2026, the company is clearly pivoting from clinical execution to regulatory positioning. That shift is backed by a balance sheet that now looks strong for a company without an approved product.
As of the third quarter, Mineralys reported $593.6 million in cash, cash equivalents, and investments following a $287.5 million equity raise in September. Management expects that war chest to fund operations into 2028, reducing near-term dilution risk even as losses continue. The latest quarter showed a net loss of $36.9 million, but that figure was down sharply from a year earlier as R&D spending declined following the completion of pivotal trials.
In the context of the broader portfolio, this is clearly not a reckless momentum chase. At just over 2% of reported assets, the position sits alongside other biotech names where upside depends on regulatory outcomes rather than market beta. One important thing for investors to keep in mind: Once a biotech is funded through approval, the risk profile quietly changes.
Glossary
13F assets under management (AUM): The total value of securities a fund reports to the SEC on Form 13F.
Clinical-stage biopharmaceutical: A company focused on developing drugs that are still being tested in clinical trials, not yet approved for sale.
Aldosterone synthase inhibitor: A drug that blocks the enzyme responsible for producing aldosterone, a hormone linked to high blood pressure.
Resistant hypertension: High blood pressure that remains uncontrolled despite using multiple antihypertensive medications.
Proprietary therapies: Treatments developed and owned by a company, often protected by patents or exclusive rights.
Outperforming the S&P 500: Achieving a higher return than the S&P 500 index over a specified period.
Stake: The ownership or investment a person or entity holds in a company.
TTM: The 12-month period ending with the most recent quarterly report.
Position: The amount of a particular security or asset held by an investor or fund.
Assets under management (AUM): The total market value of investments managed by a fund or investment firm.
Biotechnology company: A business that uses biological processes to develop products, often in healthcare or pharmaceuticals.
Commercialization: The process of bringing a new product or drug to the market for sale.
Where to invest $1,000 right now
When our analyst team has a stock tip, it can pay to listen. After all, Stock Advisor’s total average return is 975%* — a market-crushing outperformance compared to 193% for the S&P 500.
They just revealed what they believe are the 10 best stocks for investors to buy right now, available when you join Stock Advisor.
See the stocks »
*Stock Advisor returns as of December 23, 2025.
Jonathan Ponciano has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Meta Platforms. The Motley Fool recommends Legend Biotech and Mineralys Therapeutics. The Motley Fool has a disclosure policy.
Recommended Articles
